Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Teams with Topin to Market OnDose to Oncologists

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has chosen Topin & Associates to help with its marketing strategy for a molecular diagnostic test to determine proper dosing for cancer drug 5-fluorouracil.

Under the terms of the deal, Topin will create a marketing strategy around the test, called OnDose, and prepare material in order to aid Myriad's sales force in selling the test to oncologists.

OnDose, which was launched in 2009, measures the level of 5-fluorouracil from a patient's blood sample. Using that information, a physician can make better dosing decisions to improve efficacy and reduce toxicity.

5-fluorouracil is used primarily in colorectal cancer and pancreatic cancer.

Topin and its medical educational partner, Advanced Clinical Concepts, also will conduct meetings in which the OnDose technology will be discussed in greater detail and compared with other methods of determining 5-fluorouracil measurement, including the body surface area method, the current standard for determining dosing of the drug.

Financial and other terms of the deal were not disclosed.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.